Netherlands-based drugmaker Mylan (Nasdaq: MYL) has launched three antiretroviral medicines in Canada.
One of the products is Mylan’s emtricitabine/tenofovir disoproxil fumarate 200mg/300mg, a copy of US biotech major Gilead Sciences’ (Nasdaq: GILD) Truvada, for which Mylan received final approval from Health Canada along with two others.
These are Mylan’s efavirenz/emtricitabine/tenofovir disoproxil fumarate 600mg, 200mg, and 300mg, a generic alternative to Atripla, from Gilead and US drugmaker Bristol-Myers Squibb (NYSE: BMY), and tenofovir disoproxil 300mg, a generic alternative to Gilead’s Viread.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze